Decrease in shunt volume in patients with cryptogenic stroke and patent foramen ovale

BMC Neurology

Volumn 10, Issue , 2010, Pages

  Tanislav, Christian ^a   Kaps, Manfred ^a   Jauss, Marek ^a,b   Stolz, Erwin ^a   Pabst, Wolfgang ^a   Nedelmann, Max ^a   Grebe, Mathias ^a   Reichenberger, Frank ^a   Allendoerfer, Jens ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Department of Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; HEART RIGHT LEFT SHUNT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATENT FORAMEN OVALE; SIGNAL TRANSDUCTION; STROKE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SECONDARY PREVENTION; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FORAMEN OVALE, PATENT; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 78650618920     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-10-123     Document Type: Article

References (34)

1. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318:1148-1152. 10.1056/NEJM198805053181802, 3362165.
2. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 2007, 357:2262-2268. 10.1056/NEJMoa071422, 18046029.
3. Devuyst G, Bogousslavsky J. Patent foramen ovale: the never-ending story. Curr Treat Options Cardiovasc Med 2005, 7:227-239. 10.1007/s11936-005-0051-x, 16004854.
4. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 2007, 357:2262-2268. 10.1056/NEJMoa071422, 18046029.
5. De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, et al. Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke 2000, 31:2407-2413.
6. Schneider B, Hofmann T, Justen MH, Meinertz T. Chiari's network: normal anatomic variant or risk factor for arterial embolic events?. J Am Coll Cardiol 1995, 26:203-210. 10.1016/0735-1097(95)00144-O, 7797753.
7. Dorr M, Hummel A. Images in clinical medicine. Paradoxical embolism--thrombus in a patent foramen ovale. N Engl J Med 2007, 357:2285. 10.1056/NEJMicm066931, 18046032.
8. Loscalzo J. Paradoxical embolism: clinical presentation, diagnostic strategies, and therapeutic options. Am Heart J 1986, 112:141-145. 10.1016/0002-8703(86)90692-7, 3728270.
9. Meacham RR, Headley AS, Bronze MS, Lewis JB, Rester MM. Impending paradoxical embolism. Arch Intern Med 1998, 158:438-448. 10.1001/archinte.158.5.438, 9508221.
10. Ozdemir AO, Tamayo A, Munoz C, Dias B, Spence JD. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J Neurol Sci 2008, 275:121-127. 10.1016/j.jns.2008.08.018, 18822432.
11. Feurer R, Sadikovic S, Esposito L, Schwarze J, Bockelbrink A, Hemmer B, et al. Lesion patterns in patients with cryptogenic stroke with and without right-to-left-shunt. Eur J Neurol 2009, 16:1077-1082. 10.1111/j.1468-1331.2009.02692.x, 19486130.
12. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002, 105:2625-2631. 10.1161/01.CIR.0000017498.88393.44, 12045168.
13. Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology 2009, 73:89-97. 10.1212/WNL.0b013e3181aa2a19, 19439720.
14. Zerio C, Canterin FA, Pavan D, Nicolosi GL. Spontaneous closure of a patent foramen ovale and disappearance of impending paradoxical embolism after fibrinolytic therapy in the course of massive pulmonary embolism. Am J Cardiol 1995, 76:422-424. 10.1016/S0002-9149(99)80118-0, 7639177.
15. Inoue T, Yamaguchi H, Hayashi T, Morooka S, Takabatake Y. Right-to-left shunting through a patent foramen ovale caused by pulmonary hypertension associated with rheumatoid arthritis and Sjogren's syndrome: a case report. Angiology 1990, 41:1082-1085. 10.1177/000331979004101210, 2278405.
16. Jauss M, Zanette E. Detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler sonography. Cerebrovasc Dis 2000, 10:490-496. 10.1159/000016119, 11070388.
17. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
18. Anzola GP, Zavarize P, Morandi E, Rozzini L, Parrinello G. Transcranial Doppler and risk of recurrence in patients with stroke and patent foramen ovale. Eur J Neurol 2003, 10:129-135. 10.1046/j.1468-1331.2003.00561.x, 12603287.
19. Belvis R, Leta RG, Marti-Fabregas J, Cocho D, Carreras F, Pons-Llado G, et al. Almost perfect concordance between simultaneous transcranial Doppler and transesophageal echocardiography in the quantification of right-to-left shunts. J Neuroimaging 2006, 16:133-138. 10.1111/j.1552-6569.2006.00021.x, 16629735.
20. Droste DW, Kriete JU, Stypmann J, Castrucci M, Wichter T, Tietje R, et al. Contrast transcranial Doppler ultrasound in the detection of right-to-left shunts: comparison of different procedures and different contrast agents. Stroke 1999, 30:1827-1832.
21. Inoue T, Yamaguchi H, Hayashi T, Morooka S, Takabatake Y. Right-to-left shunting through a patent foramen ovale caused by pulmonary hypertension associated with rheumatoid arthritis and Sjogren's syndrome: a case report. Angiology 1990, 41:1082-1085. 10.1177/000331979004101210, 2278405.
22. Zerio C, Canterin FA, Pavan D, Nicolosi GL. Spontaneous closure of a patent foramen ovale and disappearance of impending paradoxical embolism after fibrinolytic therapy in the course of massive pulmonary embolism. Am J Cardiol 1995, 76:422-424. 10.1016/S0002-9149(99)80118-0, 7639177.
23. Widimsky J. The mechanism of pulmonary hypertension in pulmonary embolism. Bull Physiopathol Respir (Nancy) 1970, 6:147-184.
24. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002, 121:877-905. 10.1378/chest.121.3.877, 11888976.
25. Cuppini S, Cattelan AM, Casara D, Prandoni P. Occult pulmonary embolism in patients with proximal deep venous thrombosis. Ann Ital Med Int 1991, 6:1-5.
26. Huisman MV, Buller HR, ten Cate JW, van Royen EA, Vreeken J, Kersten MJ, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989, 95:498-502. 10.1378/chest.95.3.498, 2920574.
27. Jimenez D, Diaz G, Marin E, Vidal R, Sueiro A, Yusen RD. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost 2006, 95:562-566.
28. Lopez-Beret P, Pinto JM, Romero A, Orgaz A, Fontcuberta J, Oblas M. Systematic study of occult pulmonary thromboembolism in patients with deep venous thrombosis. J Vasc Surg 2001, 33:515-521. 10.1067/mva.2001.111978, 11241121.
29. Meignan M, Rosso J, Gauthier H, Brunengo F, Claudel S, Sagnard L, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000, 160:159-164. 10.1001/archinte.160.2.159, 10647753.
30. Stone DA, Godard J, Corretti MC, Kittner SJ, Sample C, Price TR, et al. Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J 1996, 131:158-161. 10.1016/S0002-8703(96)90065-4, 8554004.
31. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001, 38:613-623. 10.1016/S0735-1097(01)01427-9, 11527606.
32. Harrer JU, Wessels T, Franke A, Lucas S, Berlit P, Klotzsch C. Stroke recurrence and its prevention in patients with patent foramen ovale. Can J Neurol Sci 2006, 33:39-47.
33. Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol 2005, 101:77-82. 10.1016/j.ijcard.2004.03.005, 15860387.
34. NMT Medical Announces Preliminary Results of CLOSURE I PFO/Stroke Trial Primary End-point Not Achieved; Trial Demonstrates Slight Benefit Over Current Best Medical Therapy. Company Release 2010, NMT Medical Announces Preliminary Results of CLOSURE I PFO/Stroke Trial.